Scarica l'app Stockscreener
2.65
4.80%
0.13
Dopo l'orario di chiusura:
2.64
-0.010
-0.38%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ESPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.52
Aprire:
$2.53
Volume 24 ore:
5.21M
Relative Volume:
0.77
Capitalizzazione di mercato:
$534.30M
Reddito:
$116.33M
Utile/perdita netta:
$-209.25M
Rapporto P/E:
-1.25
EPS:
-2.12
Flusso di cassa netto:
$-135.49M
1 W Prestazione:
+7.58%
1M Prestazione:
-4.66%
6M Prestazione:
+173.99%
1 anno Prestazione:
+24.58%
Intervallo 1D:
$2.52
$2.68
Intervallo di 1 settimana:
$2.44
$2.755
Portata 52W:
$0.6925
$3.94
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Nome
Esperion Therapeutics Inc
Settore
Telefono
734-887-3903
Indirizzo
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Confronta ESPR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.65 | 625.38M | 116.33M | -209.25M | -135.49M | -2.12 |
|
ZTS
Zoetis Inc
|
143.24 | 63.58B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.89 | 43.58B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.185 | 40.83B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.62 | 23.07B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
432.69 | 19.61B | 3.08B | 1.24B | 1.07B | 25.61 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Iniziato | Goldman | Neutral |
| 2024-12-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-20 | Ripresa | JP Morgan | Neutral |
| 2023-08-01 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2023-03-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Ripresa | BofA Securities | Neutral |
| 2023-02-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Downgrade | Stifel | Buy → Hold |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-03-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Downgrade | Jefferies | Buy → Hold |
| 2021-02-09 | Downgrade | Goldman | Neutral → Sell |
| 2021-01-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-11-10 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Ripresa | JP Morgan | Underweight |
| 2020-08-11 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Ripresa | BofA/Merrill | Buy |
| 2020-03-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-02-24 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2019-09-16 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-06 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Aggiornamento | Goldman | Sell → Neutral |
| 2019-03-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Reiterato | Needham | Strong Buy |
| 2018-12-13 | Iniziato | Goldman | Sell |
| 2018-10-29 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Iniziato | BTIG Research | Buy |
| 2018-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2018-07-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Downgrade | BofA/Merrill | Buy → Underperform |
Mostra tutto
Esperion Therapeutics Inc Borsa (ESPR) Ultime notizie
Published on: 2025-10-15 12:04:18 - newser.com
How to use Fibonacci retracement on Esperion Therapeutics Inc.Market Growth Summary & AI Forecast for Swing Trade Picks - newser.com
Why Esperion Therapeutics Inc. stock is favored by top institutionsInsider Selling & Real-Time Stock Movement Alerts - newser.com
Why Esperion Therapeutics Inc. is moving todayWeekly Trade Review & Real-Time Stock Movement Alerts - newser.com
How to integrate Esperion Therapeutics Inc. into portfolio analysis toolsJuly 2025 Trends & Real-Time Chart Breakout Alerts - newser.com
Esperion Therapeutics Inc. stock momentum explained2025 Geopolitical Influence & Low Risk High Reward Ideas - newser.com
How to use a screener to detect Esperion Therapeutics Inc. breakoutsPortfolio Gains Report & Proven Capital Preservation Methods - newser.com
Identifying reversal signals in Esperion Therapeutics Inc.July 2025 Opening Moves & Consistent Income Trade Ideas - newser.com
What’s the recovery path for long term holders of Esperion Therapeutics Inc.Trend Reversal & Safe Investment Capital Preservation Plans - newser.com
Esperion Therapeutics Inc. (ESPR) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Will Esperion Therapeutics Inc. stock gain from lower inflation2025 Trading Volume Trends & Safe Entry Momentum Stock Tips - newser.com
Why analysts remain bullish on Esperion Therapeutics Inc. stockQuarterly Profit Report & Fast Entry and Exit Trade Plans - newser.com
Analyzing drawdowns of Esperion Therapeutics Inc. with statistical toolsJuly 2025 Breakouts & Verified Entry Point Signals - newser.com
Published on: 2025-10-13 11:11:10 - newser.com
What analysts say about MarketAxess Holdings Inc stockMarket Liquidity Analysis & Rapid Portfolio Expansion - earlytimes.in
Published on: 2025-10-13 10:12:04 - newser.com
Published on: 2025-10-13 10:10:18 - newser.com
Can Esperion Therapeutics Inc. stock reach $100 price targetEarnings Beat & AI Enhanced Trading Signals - newser.com
How strong is Esperion Therapeutics Inc. stock balance sheet2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs - MSN
Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop - Yahoo Finance
Will Esperion Therapeutics Inc. stock benefit from upcoming earnings reportsJuly 2025 Fed Impact & Advanced Technical Analysis Signals - newser.com
Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News - Yahoo Finance
How currency fluctuations impact Esperion Therapeutics Inc. stockTake Profit & Fast Momentum Entry Tips - newser.com
Why Is Esperion Therapeutics Stock Sinking Premarket Today? - Stocktwits
Is Esperion Therapeutics Inc. stock attractive for hedge fundsJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play - Yahoo Finance
(10/10/25) ESPR: Japanese Drug Approval, Otsuka Payments to Help this Biote - moneyshow.com
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering - sharewise.com
Is Esperion Therapeutics Inc. stock a buy on dips2025 Trading Volume Trends & Safe Entry Trade Reports - newser.com
Published on: 2025-10-09 02:49:28 - newser.com
Esperion Therapeutics (NASDAQ:ESPR) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Esperion Announces Public Offering to Raise $70.2 Million - TipRanks
Esperion Therapeutics Down Over 15%, on Pace for Largest Percent Decrease Since December 2024 -- Data Talk - 富途牛牛
Esperion Therapeutics (NASDAQ:ESPR) Shares Gap DownShould You Sell? - MarketBeat
Esperion Therapeutics’ Bold Move: Stock Offering at $2.50 - StocksToTrade
Esperion Therapeutics prices $75M public offering - MSN
Penguin Solutions Posts Q4 Earnings, Joins Esperion Therapeutics, Joby Aviation And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Esperion Therapeutics Inc Azioni (ESPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Esperion Therapeutics Inc Azioni (ESPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Koenig Sheldon L. | President and CEO |
Sep 17 '25 |
Sale |
2.79 |
28,427 |
79,254 |
1,518,831 |
| Halladay Benjamin | Chief Financial Officer |
Sep 17 '25 |
Sale |
2.81 |
7,046 |
19,785 |
474,862 |
0.02%
5.80%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):